{"id":"https://openalex.org/W2785169786","doi":"https://doi.org/10.1182/blood.v130.suppl_1.640.640","title":"A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies","display_name":"A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies","publication_year":2017,"publication_date":"2017-12-07","ids":{"openalex":"https://openalex.org/W2785169786","doi":"https://doi.org/10.1182/blood.v130.suppl_1.640.640","mag":"2785169786"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v130.suppl_1.640.640","doi":"https://doi.org/10.1182/blood.v130.suppl_1.640.640","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v130.suppl_1.640.640","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067521829","display_name":"Amer Methqal Zeidan","orcid":"https://orcid.org/0000-0001-7017-8160","observed_orcids":["https://orcid.org/0000-0001-7017-8160"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amer M. Zeidan","raw_affiliation_strings":["Section of Hematology, Department of Internal Medicine, Yale Cancer Center, East Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Hematology, Department of Internal Medicine, Yale Cancer Center, East Haven, CT","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070277385","display_name":"Rachel J. Cook","orcid":"https://orcid.org/0000-0001-7005-036X","observed_orcids":["https://orcid.org/0000-0001-7005-036X"]},"institutions":[{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel J. Cook","raw_affiliation_strings":["Knight Cancer Institute, Oregon Health and Science University, Portland, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR","institution_ids":["https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062558399","display_name":"Rodolfo Eduardo Bordoni","orcid":"https://orcid.org/0000-0003-0499-4471","observed_orcids":["https://orcid.org/0000-0003-0499-4471"]},"institutions":[{"id":"https://openalex.org/I4210156026","display_name":"Georgia Cancer Specialists","ror":"https://ror.org/057c61d28","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210156026"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Rodolfo Bordoni","raw_affiliation_strings":["Georgia Cancer Specialists, Marietta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Georgia Cancer Specialists, Marietta, GA","institution_ids":["https://openalex.org/I4210156026"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108297819","display_name":"Ekaterine Asatiani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ekaterine Asatiani","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100991398","display_name":"Gongfu Zhou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Gongfu Zhou","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087218547","display_name":"Th\u00e9a Faivre","orcid":"https://orcid.org/0000-0003-2090-2477","observed_orcids":["https://orcid.org/0000-0003-2090-2477"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Th\u00e9a Faivre","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040815890","display_name":"Michael Thomas Byrne","orcid":"https://orcid.org/0000-0002-2966-4877","observed_orcids":["https://orcid.org/0000-0002-2966-4877"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Byrne","raw_affiliation_strings":["Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Savona","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN","institution_ids":["https://openalex.org/I901861585"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5062558399","https://openalex.org/A5087218547","https://openalex.org/A5100991398"],"corresponding_institution_ids":["https://openalex.org/I4210156026","https://openalex.org/I924451375"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"130","issue":"Suppl_1","first_page":"640","last_page":"640"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11503","display_name":"Cytokine Signaling Pathways and Interactions","score":0.75,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11503","display_name":"Cytokine Signaling Pathways and Interactions","score":0.75,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.20340000092983246,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.009100000374019146,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/jak1-inhibitor","display_name":"JAK1 inhibitor","score":0.9900000095367432},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.8360000252723694},{"id":"https://openalex.org/keywords/advanced-hematologic-malignancies","display_name":"advanced hematologic malignancies","score":0.9100000262260437},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9929999709129333},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9929999709129333},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9129999876022339},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.7699999809265137},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9959999918937683},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7289999723434448},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8389999866485596},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5490000247955322},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.5870000123977661}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8185173273086548},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.755212664604187},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.729744017124176},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6250792145729065},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5478931069374084},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5176961421966553},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.47958365082740784},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.42339470982551575},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.3628841042518616},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35892340540885925},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2958553433418274},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2800518870353699},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2181113362312317}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v130.suppl_1.640.640","doi":"https://doi.org/10.1182/blood.v130.suppl_1.640.640","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v130.suppl_1.640.640","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4206670996","https://openalex.org/W2909464822","https://openalex.org/W2500913985","https://openalex.org/W2607481702","https://openalex.org/W2886219353","https://openalex.org/W2740068758","https://openalex.org/W2588030565","https://openalex.org/W4376956398","https://openalex.org/W2967196784","https://openalex.org/W2566866744"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"The":[2,147,329,472,497],"JAK/STAT":[3,19],"pathway":[4,20],"plays":[5],"an":[6,40,635,681,693,716,733,744,756,769],"important":[7],"role":[8],"in":[9,39,50,55,112,119,125,142,161,187,229,258,316,325,359,457,469,516,528,555,559,597,603],"cytokine":[10],"and":[11,63,79,99,108,191,208,216,221,223,233,320,378,380,392,436,494,535,589,606],"growth":[12],"factor":[13],"signal":[14],"transduction.":[15],"Dysregulation":[16],"of":[17,26,45,72,213,225,323,333,361,367,382,585,595,638,684,696,719,736,747,759,772],"the":[18,24,250,259,317,326,406,458,517,529,583],"is":[21,36,182,601],"associated":[22],"with":[23,52,57,90,114,121,127,144,189,198,231,254,294,405,430,444,455,466,482,485,487,504,514,526,557,561],"pathogenesis":[25],"various":[27],"hematologic":[28,59,92],"malignancies.":[29,60],"INCB052793,":[30],"a":[31,73,150,463,467],"small":[32],"molecule":[33],"JAK1":[34],"inhibitor,":[35],"being":[37,409],"evaluated":[38,105],"ongoing":[41,602],"phase":[42,87,544,604],"1/2":[43,545],"study":[44,148,171,203,439],"INCB052793":[46,95,106,184,214,226,284,338,364,427,549,575,596],"as":[47,336],"monotherapy":[48,74,96,215],"or":[49,124,136,165,177,417,506,579,640,686,698,721,738,749,761,774],"combination":[51,80,120,143,185,217,227,287,300,556],"standard":[53],"therapies":[54],"patients":[56,89,113,126,188,230,253,266,293,297,315,324,362,368,383,395,424,454,481,503,513,525,560,581],"advanced":[58,91,115,128,562],"Preliminary":[61,540,587],"safety":[62,222,588],"efficacy":[64,224,590],"data":[65,248,261,441,572,591],"are":[66],"reported.":[67],"Methods:":[68],"Phase":[69,103,180],"1":[70,429,488,490,532,536],"consisted":[71],"dose":[75,82,209],"escalation":[76],"(phase":[77,84,219,236],"1a)":[78],"therapy":[81,186,197,218,228,288,301],"expansion":[83,212],"1b).":[85],"In":[86],"1a,":[88],"malignancies":[93,256],"received":[94,283,290,298,312,426,509],"(25,":[97],"35,":[98],"50":[100],"mg":[101,110],"QD).":[102],"1b":[104],"(25":[107],"35":[109],"QD)":[111],"multiple":[116],"myeloma":[117],"(MM)":[118],"dexamethasone":[122],"(DEX);":[123],"acute":[129],"myeloid":[130,563],"leukemia":[131],"(AML),":[132],"myelodysplastic":[133],"syndrome":[134],"(MDS),":[135],"MDS/myeloproliferative":[137],"neoplasm":[138],"(MPN)":[139],"overlap":[140],"syndromes":[141],"azacitidine":[145],"(AZA).":[146],"employed":[149],"3+3":[151],"dose-escalation":[152],"design":[153],"until":[154,170],"dose-limiting":[155],"toxicities":[156],"occurred.":[157],"Patients":[158],"were":[159,239,357],"treated":[160,484],"continuous":[162],"21-day":[163],"(monotherapy)":[164],"28-day":[166],"(combination":[167],"therapy)":[168],"cycles":[169],"termination,":[172],"consent":[173],"withdrawal,":[174],"disease":[175,410],"progression,":[176],"unacceptable":[178],"toxicity.":[179],"2":[181,443,461,524,605],"evaluating":[183],"AML":[190,232,483],"high-risk":[192],"MDS":[193,235,505,515],"who":[194,425,508,567],"failed":[195,569],"prior":[196],"hypomethylating":[199],"agents":[200],"(HMAs).":[201],"Primary":[202],"objectives":[204],"included":[205],"safety,":[206],"tolerability,":[207],"selection":[210],"for":[211,480,502],"1)":[220,356],"higher-risk":[234],"2).":[237,451],"Responses":[238],"recorded":[240],"according":[241],"to":[242,582],"malignancy-specific":[243],"criteria.":[244],"Results:":[245],"We":[246],"report":[247],"on":[249,438,634,680,692,715,732,743,755,768],"first":[251],"39":[252],"hematological":[255],"enrolled":[257],"study.At":[260],"cutoff":[262],"(June":[263],"19,":[264],"2017),11":[265],"(MDS/MPN,":[267],"n=4;":[268],"MM,":[269],"n=3;":[270],"diffuse":[271],"large":[272],"B-cell":[273],"lymphoma,":[274,281],"n=2;":[275],"chronic":[276],"lymphocytic":[277],"leukemia,":[278],"n=1;":[279],"Hodgkin's":[280],"n=1)":[282],"monotherapy.":[285],"INCB052793+DEX":[286,318,370,459],"was":[289,311,335,477,499],"by":[291,313],"7":[292,453,512],"MM;":[295],"21":[296],"INCB052793+AZA":[299,327,385,518,530],"(AML,":[302],"n=12;":[303],"MDS,":[304],"n=7;":[305],"MDS/MPN,":[306],"n=2).":[307],"Prior":[308],"HMA":[309],"treatment":[310,334,397],"0":[314],"group":[319],"71.4%":[321],"(15/21)":[322],"group.":[328],"median":[330],"(range)":[331],"duration":[332],"follows:":[337],"monotherapy,":[339,365,399,413,428],"104":[340],"(14\u2012528)":[341],"days;":[342,346],"INCB052793+DEX,":[343,401,415],"51":[344],"(15\u201296)":[345],"INCB052793+AZA,":[347,403,486],"125":[348],"(15\u2012456)":[349],"days.":[350],"Grade":[351],"\u22653":[352],"adverse":[353,418],"events":[354],"(Table":[355],"observed":[358],"45%":[360],"receiving":[363,369,384],"86%":[366],"(most":[371,386],"common:":[372,387],"anemia,":[373,390],"hypercalcemia,":[374],"hypophosphatemia,":[375],"pneumonia,":[376],"sepsis,":[377],"thrombocytopenia),":[379],"95%":[381],"febrile":[388],"neutropenia,":[389,391],"thrombocytopenia).":[393],"Most":[394],"discontinued":[396],"(INCB052793":[398,412],"91%;":[400],"100%;":[402],"90%),":[404],"primary":[407],"reasons":[408],"progression":[411],"55%;":[414],"57%)":[416],"event":[419],"(INCB052793+AZA,":[420],"24%).":[421],"Of":[422,452,511,523],"11":[423],"MDS/MPN":[431,445,507,527],"had":[432,446,462,521,533,537],"complete":[433],"response":[434,465,474],"(CR)":[435],"remains":[437],"at":[440],"cutoff;":[442],"partial":[447],"remission":[448],"(PR;":[449],"Table":[450],"MM":[456],"group,":[460,519,531],"minimal":[464],"reduction":[468],"M":[470],"protein.":[471],"overall":[473],"rate":[475],"(ORR)":[476],"67%":[478],"(8/12)":[479],"CR,":[489],"morphologic":[491],"leukemia-free":[492],"state,":[493],"6":[495],"PRs.":[496],"ORR":[498],"56%":[500],"(5/9)":[501],"INCB052793+AZA.":[510],"3":[520],"CR.":[522],"CR":[534],"PR.":[538],"Conclusion:":[539],"findings":[541],"from":[542],"this":[543,598],"trial":[546],"indicate":[547,573],"that":[548,574],"has":[550],"encouraging":[551],"clinical":[552],"activity,":[553],"especially":[554],"AZA,":[558],"malignancies,":[564],"including":[565,609],"those":[566],"previously":[568],"HMAs.":[570,586],"These":[571],"might":[576],"(re)-sensitize":[577],"HMA-refractory":[578],"relapsed":[580],"effects":[584],"support":[592],"further":[593],"evaluation":[594],"setting.":[599],"Enrolment":[600],"expanded":[607],"data,":[608],"PK/PD,":[610],"will":[611],"be":[612],"presented.":[613],"Disclosures":[614],"Zeidan:":[615],"Otsuka:":[616],"Consultancy;":[617],"Takeda:":[618,710],"Speakers":[619,646,650,654],"Bureau;":[620,647,651],"AbbVie,":[621],"Otsuka,":[622],"Pfizer,":[623],"Gilead,":[624],"Celgene,":[625],"Ariad,":[626],"Incyte:":[627],"Consultancy,":[628,707,727],"Honoraria.":[629],"Cook:":[630],"Syros":[631],"Corporation:":[632,658,664,670,706],"Membership":[633,679,691,714,731,742,754,767],"entity's":[636,682,694,717,734,745,757,770],"Board":[637,683,695,718,735,746,758,771],"Directors":[639,685,697,720,737,748,760,773],"advisory":[641,687,699,722,739,750,762,775],"committees.":[642,700,776],"Bordoni:":[643],"Merck:":[644],"Honoraria,":[645,649,653],"Genentech:":[648],"Abbvie:":[652],"Bureau.":[655],"Asatiani:":[656],"Incyte":[657,663,669,705],"Employment,":[659,665,671],"Equity":[660,666,672,728],"Ownership.":[661,667,673],"Zhou:":[662],"Faivre:":[668],"Byrne:":[674],"Karyopharm:":[675,726],"Research":[676,703,708,711,724,764],"Funding;":[677,704,709,712,725,765],"Pfizer:":[678],"committees;":[688,740,751],"Concert":[689],"Pharmaceuticals:":[690],"Savona:":[701],"Sunesis:":[702],"Astex:":[713],"committees,":[723,763],"Ownership;":[729],"Gilead:":[730],"Celgene:":[741],"TG":[752],"Therapeutics:":[753],"Amgen:":[766]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-02-02T00:00:00"}